ConductScience.org, home

Paper36769018

Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1.

Stoodley J and 5 others. Int J Mol Sci, 2023. Cited by 18 papers, by iCite.

Cite this record

ConductScience Library. Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1. Papers, record 36769018. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36769018

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
18
iCite
Relative citation ratio, by iCite
2.02
iCite
Revised in PubMed
2025-05-30
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Stoodley JJessicahttps://orcid.org/0000-0003-4406-9002
2Vallejo-Bedia FFranciscohttps://orcid.org/0000-0001-5366-6736
3Seone-Miraz DDavid
4Debasa-Mouce MManuelhttps://orcid.org/0000-0001-9511-7399
5Wood MJAMatthew J A
6Varela MAMiguel A

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Myotonic DystrophyMajor topic
Muscular DystrophiesMajor topic
Mice
Animals
Tissue Distribution
Oligonucleotides, Antisense
Myocardium

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
MR/P01741X/1Medical Research CouncilUnited KingdomPubMed
MR/W014742/1Medical Research CouncilUnited KingdomPubMed

Source PubMed

Download CSV of grants

References98

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122861906Psychiatric and cognitive phenotype of childhood myotonic dystrophy type 1.Dev Med Child Neurol2012https://conductscience.org/library/papers/22861906PubMed
28378346Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.Proc Natl Acad Sci U S A1993https://conductscience.org/library/papers/8378346PubMed
334385691Cholesterol-functionalized DNA/RNA heteroduplexes cross the blood-brain barrier and knock down genes in the rodent CNS.Nat Biotechnol2021https://conductscience.org/library/papers/34385691PubMed
4122402553'-amino-2',4'-BNA: novel bridged nucleic acids having an N3'-->P5' phosphoramidate linkage.Chem Commun (Camb)2001https://conductscience.org/library/papers/12240255PubMed
510655554Dramatic, expansion-biased, age-dependent, tissue-specific somatic mosaicism in a transgenic mouse model of triplet repeat instability.Hum Mol Genet2000https://conductscience.org/library/papers/10655554PubMed
633821570Delivery of oligonucleotide-based therapeutics: challenges and opportunities.EMBO Mol Med2021https://conductscience.org/library/papers/33821570PubMed
731479430Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice.J Clin Invest2019https://conductscience.org/library/papers/31479430PubMed
825753670Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy.Nucleic Acids Res2015https://conductscience.org/library/papers/25753670PubMed
918784278Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function.Hum Mol Genet2008https://conductscience.org/library/papers/18784278PubMed
1011359466Epidemiology of myotonic dystrophy in Italy: re-apprisal after genetic diagnosis.Clin Genet2001https://conductscience.org/library/papers/11359466PubMed
1131376426Targeting the transferrin receptor for brain drug delivery.Prog Neurobiol2019https://conductscience.org/library/papers/31376426PubMed
1211528389Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy.Nat Genet2001https://conductscience.org/library/papers/11528389PubMed
131303233Correlation between CTG trinucleotide repeat length and frequency of severe congenital myotonic dystrophy.Nat Genet1992https://conductscience.org/library/papers/1303233PubMed
1420603324CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1.Hum Mol Genet2010https://conductscience.org/library/papers/20603324PubMed
157896884Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues.J Cell Biol1995https://conductscience.org/library/papers/7896884PubMed
1619767415Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population.Brain2009https://conductscience.org/library/papers/19767415PubMed
178196473Blockade of morphine analgesia by an antisense oligodeoxynucleotide against the mu receptor.Life Sci1994https://conductscience.org/library/papers/8196473PubMed
1832242217Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.Hum Mol Genet2020https://conductscience.org/library/papers/32242217PubMed
1928009628Enhanced delivery of IL-1 receptor antagonist to the central nervous system as a novel anti-transferrin receptor-IL-1RA fusion reverses neuropathic mechanical hypersensitivity.Pain2017https://conductscience.org/library/papers/28009628PubMed
2028624222Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice.Mol Ther Nucleic Acids2017https://conductscience.org/library/papers/28624222PubMed

See all 98 referencesDownload CSV of references

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.

PMIDTitleJournalYearIn PapersSource
42339623Bottlebrush polymer conjugates for enhanced antisense oligonucleotide therapy in myotonic dystrophy type 1.Nucleic Acids Res2026https://conductscience.org/library/papers/42339623PubMed
41996006Therapeutic Strategies Targeting the Molecular Pathogenesis of Myotonic Dystrophy Type 1: Current Status and Future Directions.Mol Diagn Ther2026https://conductscience.org/library/papers/41996006PubMed
41797662Targeting Expanded CUG and CTG Repeats as a Therapeutic Approach for Myotonic Dystrophy Type 1 (DM1).ChemMedChem2026https://conductscience.org/library/papers/41797662PubMed
40938889Validation of the FVB/N-Tg(HSA* LR)20bCath mice of myotonic dystrophy using swallowing function assessment, histology, and immunofluorescence analysis.PLoS One2025https://conductscience.org/library/papers/40938889PubMed
40808372Changes in RNA splicing as a surrogate endpoint for myotonic dystrophy Type 1 (DM1) clinical trials.J Neuromuscul Dis2026https://conductscience.org/library/papers/40808372PubMed
40608957Exon skipping peptide-conjugated morpholinos downregulate dynamin 2 to rescue centronuclear myopathy.Brain2025https://conductscience.org/library/papers/40608957PubMed
40508159Multisystem Symptoms in Myotonic Dystrophy Type 1: A Management and Therapeutic Perspective.Int J Mol Sci2025https://conductscience.org/library/papers/40508159PubMed
40367190Intra-amniotic antisense oligonucleotide treatment improves phenotypes in preclinical models of spinal muscular atrophy.Sci Transl Med2025https://conductscience.org/library/papers/40367190PubMed
39910928Targeting Drug Delivery System to Skeletal Muscles: A Comprehensive Review of Different Approaches.J Cachexia Sarcopenia Muscle2025https://conductscience.org/library/papers/39910928PubMed
39565688CRISPR Diagnostics for Quantification and Rapid Diagnosis of Myotonic Dystrophy Type 1 Repeat Expansion Disorders.ACS Synth Biol2024https://conductscience.org/library/papers/39565688PubMed
38501046Structure-activity relationship study of mesyl and busyl phosphoramidate antisense oligonucleotides for unaided and PSMA-mediated uptake into prostate cancer cells.Front Chem2024https://conductscience.org/library/papers/38501046PubMed
38443798Curriculum vitae of CUG binding protein 1 (CELF1) in homeostasis and diseases: a systematic review.Cell Mol Biol Lett2024https://conductscience.org/library/papers/38443798PubMed
38165037Combinatorial effects of ion channel mis-splicing as a cause of myopathy in myotonic dystrophy.J Clin Invest2024https://conductscience.org/library/papers/38165037PubMed
37221259[Molecular therapies: present and future in neuromuscular diseases].Nervenarzt2023https://conductscience.org/library/papers/37221259PubMed

Download CSV of cited by

Genes15

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36769018

GET https://conductscience.org/api/papers/v1/36769018/references?page=2